Dmitry Vinogradov
Supernus Pharmaceuticals Company shares (Nasdaq:Presumably) hit the premarket on Thursday after Piper Sandler upgraded the neuroscience-focused drug developer to overweight from neutral, citing a promising sales path for its Parkinson’s disease treatment, Onapgo.
Analyst David Amselem argued that
https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1497253868/image_1497253868.jpg?io=getty-c-w750
Source link